Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Not three weeks and a couple of extra days
This material is not intended for human or veterinary use
Handling Guidelines Laboratory personnel should follow standard peptide handling procedures when working with tirzepatide: Store lyophilized vials at 4 F (20 C) or below in a dry, light-protected environment Allow the vial to reach room temperature before opening to prevent condensation Avoid prolonged exposure to heat, humidity, or direct light during handling Use sterile laboratory equipment when preparing experimental solutions Minimize repeated freezethaw cycles to maintain peptide stability Clearly label reconstituted samples with preparation date and concentration Reconstitution Guidelines Reconstitution methods may vary depending on experimental requirements, but typical laboratory practices include: Reconstitute the lyophilized peptide with sterile bacteriostatic water or an appropriate laboratory buffer Introduce the solvent slowly along the inside wall of the vial to reduce foaming Swirl the vial gently until the peptide is fully dissolved Store reconstituted solutions at 3646 F (28 C) for short-term experimental use Prepare aliquots where appropriate to reduce repeated freezethaw exposure Laboratory Safety Protocols When working with tirzepatide or similar research peptides, standard laboratory safety practices should be followed: Wear appropriate personal protective equipment including gloves, laboratory coat, and protective eyewear Handle all compounds within approved laboratory workspaces following institutional safety policies Avoid inhalation, ingestion, or direct contact with research materials Dispose of unused materials and laboratory waste according to institutional chemical disposal guidelines Maintain documentation and labeling for all stored research compounds All products supplied by NewBioRx are intended strictly for laboratory research and development use only
Eli Lilly experimental obesity drug Retatrutide hits up to 30% weight loss in pivotal trial Eli Lilly (NYSE:LLY) announced historic topline results from its Phase 3 TRIUMPH-1 clinical trial, showing that its next-generation investigational drug, retatrutide, helped adults with obesity or overweight lose an average of up to 30.3% of their body weight
Amerejuve is a Medspa environment focused on elective wellness
S-Acetyl-L-glutathione: activities and applications Oct 23, 2023 S-Acetyl-L-glutathione is a promising compound that has demonstrated potential in inducing lymphoma cell apoptosis, improving liver function, and supporting overall health
